Universität zu Köln

Bilstein, Andreas, Werkhaeuser, Nina, Rybachuk, Anna and Moesges, Ralph (2021). The Effectiveness of the Bacteria Derived Extremolyte Ectoine for the Treatment of Allergic Rhinitis. Biomed Res. Int., 2021. LONDON: HINDAWI LTD. ISSN 2314-6141

Full text not available from this repository.

Abstract

Nonpharmacological therapies with a good tolerability and safety profile are of interest to many patients with allergic rhinitis, as a relevant proportion of them have reservations about guideline-concordant pharmacological therapies due to their local irritations and side effects. Ectoine is a bacterial-derived extremolyte with an ability to protect proteins and biological membranes against damage caused by extreme conditions of salinity, drought, irradiation, pH, and temperature. Evidence from preclinical and clinical studies attests its effectiveness in the treatment of several inflammatory diseases, including allergic rhinitis. In this review, we analyzed 14 recent clinical trials investigating ectoine nasal spray in patients with allergic rhinitis and/or conjunctivitis, including sensitive patient groups like children or pregnant women. Some studies investigated monotherapy with ectoine; others investigated combination therapy of ectoine and an antihistamine or a corticosteroid. Analysis of the study results demonstrated that patients with mild-to-moderate symptoms of allergic rhinitis can be successfully treated with ectoinecontaining nasal spray. When applied as monotherapy, ectoine exerted noninferior effects compared to first-line therapies such as antihistamines and cromoglicic acid. Using ectoine as an add-on therapy to antihistamines or intranasal glucocorticosteroids accelerated symptom relief by days and improved the level of symptom relief. Importantly, concomitant treatment with ectoine was proven beneficial in a group of difficult-to-treat patients suffering from moderate-to-severe rhinitis symptoms. Taken together, the natural substance ectoine represents a viable alternative for allergic rhinitis and conjunctivitis patients who wish to avoid local reactions and side effects associated with pharmacological therapies.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Bilstein, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED Werkhaeuser, Nina UNSPECIFIED UNSPECIFIED UNSPECIFIED Rybachuk, Anna UNSPECIFIED UNSPECIFIED UNSPECIFIED Moesges, Ralph UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-589666
DOI:	10.1155/2021/5562623
Journal or Publication Title:	Biomed Res. Int.
Volume:	2021
Date:	2021
Publisher:	HINDAWI LTD
Place of Publication:	LONDON
ISSN:	2314-6141
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language COMPATIBLE SOLUTE ECTOINE; INTRANASAL THERAPY; LUNG INFLAMMATION; EPITHELIAL-CELLS; EFFICACY; SAFETY; TOLERABILITY; ORGANIZATION; FLUTICASONE; AZELASTINE Multiple languages Biotechnology & Applied Microbiology; Medicine, Research & Experimental Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/58966